Palvella Therapeutics (PVLA) Non Operating Investment Income (2026)

Palvella Therapeutics (PVLA) posted quarterly Non Operating Investment Income of $4000.0 for Q1 2026.

Palvella Therapeutics (PVLA) Non Operating Investment Income (2026) Analysis & Trends

Palvella Therapeutics (PVLA) has reported Non Operating Investment Income for 1 consecutive years, with $4000.0 the latest figure, recorded in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Palvella Therapeutics 2.25 Bn 1.93 Bn - -30,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 -30,000.00
Jun 30, 2026 -30,000.00
Mar 31, 2026 4,000.00
Mar 31, 2026 4,000.00